News

Deal Announcements

Kypha Clears Venture Capital Debt Funding

Friday, November 13, 2015 5:17:00 AM PDT | VentureDeal
   St. Louis, Missouri  --  Medical technology company Kypha has landed $2.1 million in new debt investment, according to an SEC regulatory filing.

Kypha develops and commercializes in-vitro diagnostic biomarker tests within the inflammation and autoimmune space.

The company is focused on its point of care platform called COMP ACT, which promises to deliver near real-time results to physicians.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Kypha is still seeking $1.1 million in additional financing, according to the filing.

Minimum investment size per investor was listed as $15,000.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1